11 citations
,
February 2023 in “British Journal of Pharmacology” This study found that ISX9 may activate the Wnt/β-catenin signaling pathway and holds potential as a therapeutic agent for treating alopecia.
This study identified ISX9 as a novel agonist of the Wnt/β‐catenin pathway, which promoted hair regrowth in mice and may offer a therapeutic approach for alopecia.
7 citations
,
April 2025 in “Phytomedicine” 
61 citations
,
October 2013 in “PLoS ONE” This study found that amplifying Wnt signaling, either genetically or through topical application of liposomal Wnt3a, improved skin wound healing in a mouse model.
33 citations
,
May 2017 in “Journal of Clinical Oncology” This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.